Percheron Therapeutics Limited (PER.AX)
Percheron Therapeutics Limited operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Melbourne, VIC, AU. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $4.5M. Its beta of 1.03 implies it has historically moved more than the broad market.
Percheron Therapeutics Limited, an Australian enterprise established in 2000 with its headquarters in Melbourne, is dedicated to the research and development of groundbreaking antisense pharmaceuticals. Formerly known as Antisense Therapeutics Limited until its name change in December 2023, the company holds a promising product portfolio. This includes ATL1102, an antisense inhibitor designed to target CD49d, which is currently undergoing Phase IIa clinical trials for the treatment of various inflammatory and muscular conditions such as Duchenne Muscular Dystrophy, Limb Girdle Muscular Dystrophy R2, multiple sclerosis, and asthma. Another key asset is Atesidorsen (ATL1103), an oligonucleotide that has finished Phase II clinical trials. Atesidorsen functions by blocking the growth hormone receptor, aiming to lower blood concentrations of insulin-like growth factor-I (IGF-I) and thereby address illnesses linked to an overabundance of growth hormone activity.
Percheron Therapeutics Limited is most often compared with the following Healthcare names: